|
| Year | Author | Country | HCV Ag assay | | Treatment | Sensitivity | Specificity | Concordance |
|
| 2019 | Bo Feng et al. [39] | China | Architect HCV Ag (Abbott Diagnostics) | 782 | PEG-IFN-α and ribavirin | NA | NA | NA |
| 2020 | Lin et al. [18] | | Architect HCV Ag (Abbott Diagnostics) | 110 | Paritaprevir/ritonavir, ombitasvir e dasabuvir | NA | NA | Baseline: 97.3, week 2 : 54.8, week 4 : 63.9, end: 89.7, post-W12: 98.6 |
| 2019 | Fan et al. [36] | China | Architect HCV Ag (Abbott Diagnostics) | 135 | (PEG-INF-α) and RBV | Week 12: 96.5% | Week 12: 79.5% | NA |
| 2018 | van Tilborg et al. [44] | Canada | Architect HCV Ag (Abbott Diagnostics) | 10.006 | Treatment of direct acting antivirals (excluding TVR and BOC) with or without PEG-INF, RBV | Week 4: 34.6%
End of treatment: 50%
Follow-up week 12: 98.2%
Follow-up week 24: 100% | Week 4: 86.6%
End of treatment: 97.5%
Follow-up week 12: 97.7%
Follow-up week 24: 100% | NA |
| 2018 | Chevaliez et al. [14] | NA | Architect HCV Ag (Abbott Diagnostics) | 631 | PRV boosted with ritonavir and OBV in a single pill combined with DSV | Week 4: 71.0%
Week 12: 96.2%
Posttreatment week 12: 87.5% | Week 4: 95.3%
Week 12: 97.4%
Posttreatment week 12: 98.9% | Concordance: 99.84%
Week 4: 97.05%
Week 12: 98.8%
Posttreatment week 12: 99% |
| 2017 | Łucejko et al. [46] | Europe | Architect HCV Ag (Abbott Diagnostics) | 33 | OBV/PRV/r±DSV±RBV and LDV/SOF | Day 7: 62.5%
Week 4: 50% | Day 7: 44.4%
Week 4: 81.8%
End of treatment: 100% | NA |
| 2017 | Rockstroh et al. [15] | NA | Architect HCV Ag (Abbott Diagnostics) | 737 | RTV-boosted PRV and OBV with DSV coadministered with or without RBV | NA | NA | Concordance between HCV Ag and HCV RNA in week 4 (96.46%) and posttreatment week (99.75%) |
| 2017 | Loggi et al. [48] | Italy | Architect HCV Ag (Abbott Diagnostics) | 96 | 3D±RBV; SOF±RBV; SOF+SMV±RBV; SOF+LDV±RBV; SOF+DCV; SOF+PEG-IFN-α+RBV | Week 2: 42.8% week 4: 31.25% week 8 and 12: 0% | Week 2: 84.2%
Week 4: 78.4%
Week 8: 82.1%
Week 12: 90.4%
Week 16 and 24: 100% | NA |
| 2017 | Arboledas et al. [49] | Spain | Architect HCV Ag (Abbott Diagnostics) | 262 | 2D+RBV; 3D±RBV; SOF+DAC±RBV; SOF+LED±RBV; SOF+SIM±RBV; SOF+PEG+RBV; SOF+RBV; SIM+DAC+RBV | NA | NA | Week 1: 56.7%
Week 4: 83%
End of treatment: 93.5% |
| 2017 | Lamoury et al. [11] | Australia | Architect HCV Ag (Abbott Diagnostics) | 92 | PEG-INF-α-2b and RBV | Treatment: 31%
Posttreatment: 100%
End of treatment: 56%
SVR12/24 : 100% sensitivity and specificity | Treatment: 98%
Post treatment: 100%
End of treatment: 100% | NA |
| 2017 | Alonso et al. [50] | Spain | Architect HCV Ag (Abbott Diagnostics) | 28 | Viekirax+Exviera/Harvoni/Viekirax+Exviera+RBV/Harvoni+RBV/Sovaldi/SOF+DCV/SOF+SMV+RBV | NA | End of treatment: 92.8% | NA |
| 2016 | Aghemo et al. [13] | Italy | Architect HCV Ag (Abbott Diagnostics) | 58 | PRV/RTV/OBV+DSV±RBV or SOF+SMV±RBV/SOF+RBV/PEG-IFN associate SOF+RBV/SOF+RBV or SOF+SMV±RBV | NA | NA | Concordance HCV RNA and HCV Ag: week 2: 40%; week 4: 55%; at the end of treatment, as expected, the agreement between the tests raised to 95%. |
| 2016 | Kim et al. [52] | South Korea | Architect HCV Ag (Abbott Diagnostics) | 92 | PEG-IFN-α-2a | Week 4: 33.3% | Week 4: 100% | NA |
| 2015 | Kamal et al. [53] | Egypt | Architect HCV Ag (Abbott Diagnostics) | 410 | PEG-IFN-α2a and RBV | Week 4: 100%
Week 12: 100% | Week 4: 97.5%
Week 12: 99.3% | NA |
| 2014 | Florea et al. [35] | Romania | Architect HCV Ag (Abbott Diagnostics) | 1782 | IFN+RBV | 4 weeks: 77.9%
12 weeks: 52.1%
24 weeks: 48.1%
48 weeks: 88.2%
72 week: 96.1% | 4 weeks: 100%
12 weeks: 100%
24 weeks: 100%
48 weeks: 100%
72 week: 100% | NA |
| 2005 | González et al. [21] | Spain | Orthotrak-C™ (Ortho Clinical Diagnostics) | 58 | IFN-α2α+RBV | Week 4: 42.5%
Week 12: 10.5%
24 weeks after end of: 88.9% | EOT week 4: 100%
EOT week 12: 100%
24 weeks after end of: 100% | NA |
| 2005 | Masahiko Takahashi et al. [32] | Japan | Lumipulse Ortho HCV Ag (Ortho Clinical Diagnostics) | 44 | PEG-IFN-α-2a+RBV | Week 7: 76.9%
Day 15: 74.1% | NA | Week 7: 79.5%; : 75% |
| 2004 | Soffredini et al. [31] | Italy | Orthotrak-C™ (Ortho Clinical Diagnostics) | 111 | IFN+RBV | Week 12: 70.5%
6 months after therapy: 94.2% | NA | NA |
|
